Wells Fargo & Co Reiterates “$11.00” Price Target for Mediwound (MDWD)
Mediwound (NASDAQ:MDWD) received a $11.00 price objective from equities research analysts at Wells Fargo & Co in a research note issued on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Wells Fargo & Co’s target price would suggest a potential upside of 70.54% from the company’s current price.
Other analysts also recently issued reports about the company. Oppenheimer set a $14.00 target price on Mediwound and gave the company a “buy” rating in a research note on Monday. ValuEngine upgraded Mediwound from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Finally, Zacks Investment Research downgraded Mediwound from a “hold” rating to a “sell” rating in a research note on Wednesday, July 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Mediwound has a consensus rating of “Buy” and a consensus price target of $9.79.
Shares of Mediwound stock opened at $6.45 on Tuesday. The stock has a market cap of $174.46 million, a PE ratio of -10.89 and a beta of -0.14. Mediwound has a 1-year low of $3.56 and a 1-year high of $7.35.
A number of large investors have recently bought and sold shares of MDWD. Wells Fargo & Company MN grew its stake in Mediwound by 19.9% in the first quarter. Wells Fargo & Company MN now owns 121,323 shares of the biopharmaceutical company’s stock worth $631,000 after purchasing an additional 20,134 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its stake in Mediwound by 1.0% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,098,277 shares of the biopharmaceutical company’s stock worth $14,478,000 after purchasing an additional 21,559 shares in the last quarter. Renaissance Technologies LLC grew its stake in Mediwound by 10.4% in the second quarter. Renaissance Technologies LLC now owns 130,500 shares of the biopharmaceutical company’s stock worth $900,000 after purchasing an additional 12,300 shares in the last quarter. Finally, Nexthera Capital LP acquired a new position in Mediwound in the second quarter worth about $308,000. Institutional investors and hedge funds own 32.13% of the company’s stock.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
See Also: Moving Average (MA)
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.